{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:04:25Z","timestamp":1784696665500,"version":"3.55.0"},"reference-count":59,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Antidepressants are widely prescribed medications that may affect psychomotor performance and driving ability depending on their pharmacological profile. This study investigated the prevalence and patterns of antidepressant use among drivers undergoing forensic toxicological evaluation and explored their potential implications for road safety. Methods: An observational study was conducted on n = 6316 drivers undergoing forensic toxicological assessment following licence suspension for driving under the influence (DUI) of alcohol and\/or drugs between January 2023 and December 2025. Reported antidepressants were classified into selective serotonin reuptake inhibitors (SSRIs), serotonin\u2013norepinephrine reuptake inhibitors (SNRIs), serotonin antagonist and reuptake inhibitors (SARIs), tricyclic antidepressants (TCAs), norepinephrine\u2013dopamine reuptake inhibitors (NDRIs), noradrenergic and specific serotonergic antidepressants (NaSSAs), and monoamine oxidase inhibitors (MAOIs). Distribution patterns were analysed descriptively and discussed considering the available literature. Results: Antidepressant use was reported by n = 132 participants (2.1%). SSRIs were the most common class (44.0%), followed by SNRIs (26.5%) and SARIs (17.4%). TCAs (6.1%), NDRIs (3.7%), and NaSSAs (2.3%) were less common, while no MAOI use was reported. Among antidepressant users, n = 28 individuals (21.2%) tested positive for other psychoactive substances, including benzodiazepines, cocaine, and cannabinoids. Conclusions: The use of antidepressants was relatively uncommon in the study population. However, clinical evaluation remains important, particularly at the start of treatment and during dose adjustments to determine the potential for an increased risk while driving. Further studies integrating toxicological analyses and clinical data are needed to better define the relationship between antidepressant exposure, polysubstance use, and road safety.<\/jats:p>","DOI":"10.3390\/ph19071118","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:18:31Z","timestamp":1784553511000},"page":"1118","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antidepressants and Road Safety: A Forensic Toxicological Perspective Based on Observational Data and Current Evidence"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1810-8431","authenticated-orcid":false,"given":"Davide","family":"Filardi","sequence":"first","affiliation":[{"name":"Laboratory of Forensic Toxicology, Section of Legal Medicine, Social Security and Forensic Toxicology, Department of Biomedicine and Prevention, Faculty of Medicine and Surgery, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy"},{"name":"PhD School in Medical-Surgical Applied Sciences, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2514-5471","authenticated-orcid":false,"given":"Francesca","family":"Vernich","sequence":"additional","affiliation":[{"name":"Laboratory of Forensic Toxicology, Section of Legal Medicine, Social Security and Forensic Toxicology, Department of Biomedicine and Prevention, Faculty of Medicine and Surgery, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7098-7830","authenticated-orcid":false,"given":"Federico","family":"Mineo","sequence":"additional","affiliation":[{"name":"Laboratory of Forensic Toxicology, Section of Legal Medicine, Social Security and Forensic Toxicology, Department of Biomedicine and Prevention, Faculty of Medicine and Surgery, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Mannocchi","sequence":"additional","affiliation":[{"name":"Laboratory of Forensic Toxicology, Section of Legal Medicine, Social Security and Forensic Toxicology, Department of Biomedicine and Prevention, Faculty of Medicine and Surgery, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0561-3442","authenticated-orcid":false,"given":"Roberta","family":"Tittarelli","sequence":"additional","affiliation":[{"name":"Laboratory of Forensic Toxicology, Section of Legal Medicine, Social Security and Forensic Toxicology, Department of Biomedicine and Prevention, Faculty of Medicine and Surgery, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2017). Depression and Other Common Mental Disorders: Global Health Estimates, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1001\/jama.2022.22744","article-title":"Anxiety Disorders: A Review","volume":"328","author":"Szuhany","year":"2022","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"OECD (2022). European Union Health at a Glance: Europe 2022: State of Health in the EU Cycle, OECD Publishing. Health at a Glance: Europe.","DOI":"10.1787\/507433b0-en"},{"key":"ref_4","unstructured":"Italian Medicines Agency (AIFA) (2022). National Report on Medicines Use in Italy\u2014OsMed 2021."},{"key":"ref_5","unstructured":"OECD (2021). Tackling the Mental Health Impact of the COVID-19 Crisis: An Integrated, Whole-of-Society Response, OECD Publishing."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40621-017-0107-x","article-title":"Depression, Antidepressants and Driving Safety","volume":"4","author":"Hill","year":"2017","journal-title":"Inj. Epidemiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1055\/s-0043-113572","article-title":"Driving Under the Influence of Antidepressants: A Systematic Review and Update of the Evidence of Experimental and Controlled Clinical Studies","volume":"50","author":"Brunnauer","year":"2017","journal-title":"Pharmacopsychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.clinthera.2012.04.002","article-title":"Are Selective Serotonin Reuptake Inhibitors Safe for Drivers? What Is the Evidence?","volume":"34","author":"Ravera","year":"2012","journal-title":"Clin. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1055\/s-0034-1398509","article-title":"Driving Performance and Psychomotor Function in Depressed Patients Treated with Agomelatine or Venlafaxine","volume":"48","author":"Brunnauer","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez-Abej\u00f3n, E., Herrera-G\u00f3mez, F., Criado-Espegel, P., and \u00c1lvarez, F.J. (2020). Trends in Antidepressants Use in Spain between 2015 and 2018: Analyses from a Population-Based Registry Study with Reference to Driving. Pharmaceuticals, 13.","DOI":"10.3390\/ph13040061"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1007\/s00213-022-06146-0","article-title":"Use of Psychotropic Medication and Risk of Road Traffic Crashes: A Registry-Based Case\u2013Control Study in Denmark, 1996\u20132018","volume":"239","author":"Olesen","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1080\/15389588.2024.2358093","article-title":"Driving Performance of Long-Term Users of Sedating Antidepressants and Benzodiazepines","volume":"25","author":"Westerhuis","year":"2024","journal-title":"Traffic Inj. Prev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/pds.1763","article-title":"The Impact of Medicinal Drugs on Traffic Safety: A Systematic Review of Epidemiological Studies","volume":"18","author":"Orriols","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/15389588.2024.2418361","article-title":"The Use of Prescription Medication and Other Drugs by New Zealand Drivers with Illegal Blood Alcohol Levels","volume":"26","author":"Poulsen","year":"2025","journal-title":"Traffic Inj. Prev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.4088\/JCP.v67n1116","article-title":"Antidepressants and Driving Ability: Results From a Clinical Study","volume":"67","author":"Brunnauer","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clineuro.2007.08.016","article-title":"Delirium Following Abrupt Discontinuation of Fluoxetine","volume":"110","author":"Blum","year":"2008","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/neurolint13030038","article-title":"Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1368-5031.2006.00865.x","article-title":"Tolerability and Safety of Fluvoxamine and Other Antidepressants: TOLERABILITY and SAFETY OF FLUVOXAMINE","volume":"60","author":"Westenberg","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"ref_19","unstructured":"Agenzia Italiana del Farmaco (AIFA) (2026, April 10). Riassunto delle Caratteristiche del Prodotto\u2014Fluvoxamina, Available online: https:\/\/www.google.com\/url?sa=t&source=web&rct=j&opi=89978449&url=https:\/\/api.aifa.gov.it\/aifa-bdf-eif-be\/1.0.0\/organizzazione\/1561\/farmaci\/34669\/stampati%3Fts%3DRCP&ved=2ahUKEwjFgejx5K6UAxUs2gIHHTA3HQQQFnoECA0QAQ&usg=AOvVaw2P5Q9W5_dZV1CD86URCsiF."},{"key":"ref_20","first-page":"22","article-title":"Venlafaxine and Serious Withdrawal Symptoms: Warning to Drivers","volume":"7","author":"Campagne","year":"2005","journal-title":"Medscape Gen. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.2174\/0929867324666170712165042","article-title":"New-Generation, Non-SSRI Antidepressants: Therapeutic Drug Monitoring and Pharmacological Interactions. Part 1: SNRIs, SMSs, SARIs","volume":"25","author":"Mandrioli","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_22","first-page":"3033","article-title":"Venlafaxine: A Heterocyclic Antidepressant","volume":"51","author":"Ellingrod","year":"1994","journal-title":"Am. J. Hosp. Pharm."},{"key":"ref_23","first-page":"627863","article-title":"Does Duloxetine Improve Cognitive Function Independently of Its Antidepressant Effect in Patients with Major Depressive Disorder and Subjective Reports of Cognitive Dysfunction?","volume":"2014","author":"Greer","year":"2014","journal-title":"Depress. Res. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Huang, T., Zhang, P., Zhou, Y., Wang, L., Zhang, Q., Li, M., and Xiao, J. (2025). Disproportionality Analysis of Safety Signals for Milnacipran and Levomilnacipran: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1719881"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.4088\/JCP.v69n0812","article-title":"Efficacy of Bupropion and the Selective Serotonin Reuptake Inhibitors in the Treatment of Major Depressive Disorder With High Levels of Anxiety (Anxious Depression): A Pooled Analysis of 10 Studies","volume":"69","author":"Papakostas","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00213-005-0128-y","article-title":"The Effects of Bupropion on Cognitive Functions in Healthy Subjects","volume":"182","author":"Siepmann","year":"2005","journal-title":"Psychopharmacology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1017\/S1092852922000906","article-title":"The Prescriber\u2019s Guide to Classic MAO Inhibitors (Phenelzine, Tranylcypromine, Isocarboxazid) for Treatment-Resistant Depression","volume":"28","author":"Abdelmoemin","year":"2023","journal-title":"CNS Spectr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hup.939","article-title":"The Effects of Acute Treatment with Paroxetine, Amitriptyline, and Placebo on Driving Performance and Cognitive Function in Healthy Japanese Subjects: A Double-blind Crossover Trial","volume":"23","author":"Iwamoto","year":"2008","journal-title":"Hum. Psychopharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/ijnp\/pyab031","article-title":"Driving Performance Under Treatment of Most Frequently Prescribed Drugs for Mental Disorders: A Systematic Review of Patient Studies","volume":"24","author":"Brunnauer","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1176\/appi.psy.43.1.31","article-title":"Tricyclic Antidepressants and Cognitive Decline","volume":"43","author":"Podewils","year":"2002","journal-title":"Psychosomatics"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1021\/acschemneuro.3c00591","article-title":"Classics in Chemical Neuroscience: Selegiline, Isocarboxazid, Phenelzine, and Tranylcypromine","volume":"14","author":"Hoffman","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ejphar.2014.10.032","article-title":"Mirtazapine as Positive Control Drug in Studies Examining the Effects of Antidepressants on Driving Ability","volume":"753","author":"Verster","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","article-title":"A Review of the Pharmacological and Clinical Profile of Mirtazapine","volume":"7","author":"Anttila","year":"2001","journal-title":"CNS Drug Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.4088\/JCP.v69n1205","article-title":"The Impact of Reboxetine and Mirtazapine on Driving Simulator Performance and Psychomotor Function in Depressed Patients","volume":"69","author":"Brunnauer","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hup.2321","article-title":"Effects of Repeated Dosing with Mirtazapine, Trazodone, or Placebo on Driving Performance and Cognitive Function in Healthy Volunteers","volume":"28","author":"Sasada","year":"2013","journal-title":"Hum. Psychopharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/00325481.2017.1249265","article-title":"A Review of Trazodone Use in Psychiatric and Medical Conditions","volume":"129","author":"Khouzam","year":"2017","journal-title":"Postgrad. Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ng, Q.X., Han, M.X., Teoh, S.E., Yaow, C.Y.L., Lim, Y.L., and Chee, K.T. (2021). A Systematic Review of the Clinical Use of Gabapentin and Pregabalin in Bipolar Disorder. Pharmaceuticals, 14.","DOI":"10.3390\/ph14090834"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Arnone, D., \u00d6stlundh, L., Mosa, M., MacDonald, B., Oldershaw, J., Qassem, T., and Young, A.H. (2025). Efficacy of Lamotrigine in the Treatment of Unipolar and Bipolar Depression: Meta-Analysis of Acute and Maintenance Randomised Controlled Trials. Pharmaceuticals, 18.","DOI":"10.3390\/ph18101590"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/1570159X13666150630171954","article-title":"Pharmacological Approaches for Treatment-Resistant Bipolar Disorder","volume":"13","author":"Sim","year":"2015","journal-title":"Curr. Neuropharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/hup.970","article-title":"Quetiapine Augmentation in Depressed Patients with Partial Response to Antidepressants","volume":"23","author":"Olver","year":"2008","journal-title":"Hum. Psychopharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s11096-025-02078-9","article-title":"Antidepressant Drug Use in Europe: Past Consumption, Prescribing Patterns and Forecast until 2030","volume":"48","author":"Bindel","year":"2026","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/2045125315612334","article-title":"A Review of the Management of Antidepressant Discontinuation Symptoms","volume":"5","author":"Wilson","year":"2015","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e2715","DOI":"10.1002\/hup.2715","article-title":"Driving Performance and Neurocognitive Skills of Long-term Users of Benzodiazepine Anxiolytics and Hypnotics","volume":"34","author":"Vermeeren","year":"2019","journal-title":"Hum. Psychopharmacol."},{"key":"ref_44","first-page":"13","article-title":"Driving on Antidepressants: Cruising for a Crash?","volume":"6","author":"Sansone","year":"2009","journal-title":"Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1007\/s00216-014-7763-2","article-title":"Validation of a Multi-Analyte LC\u2013MS\/MS Method for Screening and Quantification of 87 Psychoactive Drugs and Their Metabolites in Hair","volume":"406","author":"Fisichella","year":"2014","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jpba.2013.12.035","article-title":"A \u03bc-SPE Procedure for the Determination of Cannabinoids and Their Metabolites in Urine by LC\u2013MS\/MS","volume":"91","author":"Montesano","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Marchei, E., Ferri, M.A., Torrens, M., Farr\u00e9, M., Pacifici, R., Pichini, S., and Pellegrini, M. (2021). Ultra-High Performance Liquid Chromatography-High Resolution Mass Spectrometry and High-Sensitivity Gas Chromatography-Mass Spectrometry Screening of Classic Drugs and New Psychoactive Substances and Metabolites in Urine of Consumers. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084000"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-1-60761-459-3_8","article-title":"Quantitation of Benzodiazepines in Blood and Urine Using Gas Chromatography-Mass Spectrometry (GC-MS)","volume":"Volume 603","author":"Garg","year":"2010","journal-title":"Clinical Applications of Mass Spectrometry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00216-010-4471-4","article-title":"Fast GC-MS Method for the Simultaneous Screening of THC-COOH, Cocaine, Opiates and Analogues Including Buprenorphine and Fentanyl, and Their Metabolites in Urine","volume":"399","author":"Bermejo","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Tittarelli, R., Filardi, D., Mineo, F., and Mannocchi, G. (2025). A Novel and Validated GC-MS\/MS Method for the Detection of Four Opioids and Seven Fentanoids in Oral Fluid for Forensic Applications. Molecules, 30.","DOI":"10.3390\/molecules30224478"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Di Trana, A., Sprega, G., Kobidze, G., Taoussi, O., Lo Faro, A.F., Bambagiotti, G., Montanari, E., Fede, M.S., Carlier, J., and Tini, A. (2024). QuEChERS Extraction and Simultaneous Quantification in GC-MS\/MS of Hexahydrocannabinol Epimers and Their Metabolites in Whole Blood, Urine, and Oral Fluid. Molecules, 29.","DOI":"10.3390\/molecules29143440"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/dta.3526","article-title":"The Society of Hair Testing Consensus on General Recommendations for Hair Testing and Drugs of Abuse Testing in Hair","volume":"15","author":"Favretto","year":"2023","journal-title":"Drug Test. Anal."},{"key":"ref_53","first-page":"192","article-title":"Linee Guida per La Determinazione Di Sostanze Stupefacenti e Psicotrope Su Campioni Biologici Con Finalit\u00e0 Tossicologico-Forensi e Medico-Legali","volume":"19","author":"Frison","year":"2023","journal-title":"Riv. Ital. Med. Lab"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Fiorelli, D., Romani, L., Treglia, M., Pallocci, M., Passalacqua, P., Coppeta, L., Marsella, L.T., and Tittarelli, R. (2023). Carbohydrate-Deficient Transferrin (CDT) as a Biomarker of Alcohol Abuse: A Retrospective Study of the Italian Drinking Trend among Drivers from 2016 to 2022. Toxics, 11.","DOI":"10.3390\/toxics11110914"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Romani, L., Mannocchi, G., Mineo, F., Vernich, F., Stefani, L., Marsella, L.T., and Tittarelli, R. (2025). Development and Validation of a Fast and Sensitive UPLC-MS\/MS Method for Ethyl Glucuronide (EtG) in Hair, Application to Real Cases and Comparison with Carbohydrate-Deficient Transferrin (CDT) in Serum. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26031344"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cca.2016.12.022","article-title":"IFCC Approved HPLC Reference Measurement Procedure for the Alcohol Consumption Biomarker Carbohydrate-Deficient Transferrin (CDT): Its Validation and Use","volume":"465","author":"Schellenberg","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2165\/00003088-199733060-00004","article-title":"Selective Serotonin Reuptake Inhibitors and CNS Drug Interactions: A Critical Review of the Evidence","volume":"33","author":"Sproule","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"CCRep.S9540","DOI":"10.4137\/CCRep.S9540","article-title":"Serotonin Syndrome with Escitolapram and Concomitant Use of Cocaine: A Case Report","volume":"5","author":"Malik","year":"2012","journal-title":"Clin. Med. Insights Case Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"173918","DOI":"10.1016\/j.pbb.2024.173918","article-title":"Venlafaxine Treatment Is Associated with Improved Mood, but Not Decreased Cocaine Self-Administration, in Depressed People Who Use Cocaine","volume":"247","author":"Rubin","year":"2025","journal-title":"Pharmacol. Biochem. Behav."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/7\/1118\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:34:01Z","timestamp":1784694841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/7\/1118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":59,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ph19071118"],"URL":"https:\/\/doi.org\/10.3390\/ph19071118","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]}}}